Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
With the release of two new classes of antiretrovirals last fall, most care providers needed to quickly get back on the learning curve to master both drugs simultaneously. Fortunately, the new integrase inhibitor raltegravir (Isentress) has one standard dosage for all adults: one pill twice a day with or without food. It has no drug interactions and should work in any patient with HIV. However, it takes a little more study to use the other newly approved drug, maraviroc (Selzentry). When it was discovered that people are essentially resistant to HIV if they lack the CCR5 receptor on the surface of their CD4 cells, the hunt was on to find a CCR blocker. Maraviroc is the first of this class. But only about 70% to 80% of people with HIV have an R5 virus that uses CCR5 to gain access to the CD4 cell. About 2% to 5% have an X4 virus that uses another receptor, CXCR4. The remaining 20% to 30% have a virus population that is a mixture of R5 and X4. The first step in using maraviroc is to test to see if a patient has R5 virus. This test is currently available through only one laboratory. It takes two to three weeks to get results and requires a viral load of at least 1,000. The test is also expensive, but at the moment it seems to be covered by insurance. Next, the dosage may need to be raised or lower based on what other drugs the patient is taking, since maraviroc is processed through a common liver pathway called CYP 3A4. This is the pathway used by most protease inhibitors and blocked by ritonavir. Hence, the maraviroc dosage is cut in half when used in combination with a ritonavir-boosted protease inhibitor. Alternatively maraviroc must be double when used with efavirenz, which up-regulates CYP 3A4 activity. Then there are exceptions like nevirapine or boosted tipranovir, both of which cause no change in maraviroc levels. And when both a boosted PI and efavirenz are used, the boosted-PI affect wins and the dosage is halved. Confused and concerned? Don't be. The maraviroc prescribing literature has a clear chart to follow. But don't forget to review the maraviroc dosage whenever changes are made in a treatment regimen. At least it is as easy to take as raltegravir: one pill twice a day with or without food. Bowers is an HIV specialist and board-certified physician in family practice, and he is a senior partner with Pacific Oaks Medical Group, one of the largest U.S. practices devoted to HIV care, in Beverly Hills, Calif.
From our Sponsors
Most Popular
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Why activist Raif Derrazi thinks his HIV diagnosis is a gift
September 17 2024 12:00 PM
How fitness coach Tyriek Taylor reclaims his power from HIV with self-commitment
September 19 2024 12:00 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
The freedom of disclosure: David Anzuelo's journey through HIV, art, and advocacy
August 02 2024 12:21 PM
Out100 Honoree Tony Valenzuela thanks queer and trans communities for support in his HIV journey
September 18 2024 12:00 PM
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Creator and host Karl Schmid fights HIV stigma with knowledge
September 12 2024 12:03 PM
Plus: Featured Video
Latest Stories
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Check out our 2024 year-end issue!
October 28 2024 2:08 PM
Meet our Health Hero of the Year, Armonté Butler
October 21 2024 12:53 PM
AIDS/LifeCycle is ending after more than 30 years
October 17 2024 12:40 PM
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
October 15 2024 5:03 PM
Kentucky bans conversion therapy for youth as Gov. Andy Beshear signs 'monumental' order
September 18 2024 11:13 AM
Study finds use of puberty blockers safe and reversible, countering anti-trans accusations
September 11 2024 1:11 PM
Latinx health tips / Consejos de salud para latinos (in English & en espanol)
September 10 2024 4:29 PM
The Trevor Project receives $5M grant to support LGBTQ+ youth mental health in rural Midwest (exclusive)
September 03 2024 9:30 AM
Introducing 'Health PLUS Wellness': The Latinx Issue!
August 30 2024 3:06 PM
La ciencia detrás de U=U ha estado liberando a las personas con VIH durante años
August 23 2024 2:48 PM
Tratamiento y prevención del VIH por inyección: Todo lo que necesita saber
August 23 2024 2:41 PM
Sr. Gay World quiere asegurarse de que estés bien
August 23 2024 2:30 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
With a new case in Sweden, what is the new mpox outbreak and should you be concerned?
August 15 2024 4:48 PM
From ‘The Real World’ to real life: How Danny Roberts thrives with HIV
July 31 2024 5:23 PM